[1] Erdmann E,Califf R,Gerstein HC,et al. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with type 2 diabetes mellitus or prediabetes[J]. Am Heart J,2015,170(1):117-122. [2] 周颖异,成兴波,朱燕. 2型糖尿病患者血管性血友病因子与颈动脉粥样硬化相关性[J]. 江苏医药,2016,42(8):908-910. [3] 张艳秋,周广红. 糖尿病肾病患者血管性血友病因子与颈动脉病变相关性分析[J]. 医学临床研究,2017,34(1):111-112. [4] 杨海燕,潘丰慧,崔雯霞,等. PPARγ、AOPP和胱抑素C对老年2型糖尿病动脉粥样硬化的诊断价值[J]. 江苏医药,2017,43(20):1454-1457. [5] 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161. [6] Kruzliak P, Haley AP, Starcevic JN, et al. Polymorphisms of the peroxisome proliferator-activated receptor-γ (rs1801282) and its coactivator-1 (rs8192673) are associated with obesity indexes in subjects with type 2 diabetes mellitus[J]. Cardiovasc Diabetol,2015,14(1):78-79. [7] 刘瑞,朱江,赵斌,等. 2型糖尿病合并颈动脉狭窄患者血清FGF23水平与颈动脉斑块稳定性的关联性研究[J]. 神经损伤与功能重建,2017,12(3):200-203. [8] 陈超,张磊,成兴波,等. 血清成纤维细胞生长因子21与2型糖尿病患者早期大血管病变的相关性[J]. 江苏医药,2017,43(16):1154-1157. [9] 冯福奎,鄂玲玲,姜勇,等. Ⅱ型糖尿病人唾液晚期氧化蛋白产物和血浆甘油三酯含量的相关性研究[J]. 口腔颌面修复学杂志,2015,16(1):5-8. [10] 邓丽娜,罗浩虹,吕一婷,等. PPARγ2基因多态性与2型糖尿病的相关性研究[J]. 中国医药指南,2014,12(35):74-76. [11] 程万里,岳巧莲,高娟梅,等. 糖尿病患者肝脏过氧化物酶体脂肪酸代谢变化的研究[J]. 承德医学院学报,2014,31(2):118-120. [12] Pattanayak AK, Bankura B, Balmiki N, et al. Role of peroxisome proliferator-activated receptor gamma gene polymorphisms in type 2 diabetes mellitus patients of West Bengal, India[J]. J Diabetes Invest,2014,5(2):188-191. [13] Black RNA,Ennis CN,Young IS,et al. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial[J]. J Diabetes Complicat,2014,28(3):323-327. [14] 边志颖,孙倩,胡艳云,等. 新诊2型糖尿病患者血小板反应蛋白-1水平变化及其与发病机制的关系[J]. 重庆医学,2018,47(18):2418-2420. [15] 王立坤,武雪亮,杨占清,等. 2型糖尿病患者血清生物标志物水平与颈动脉斑块形成的关系[J]. 中国临床药理学杂志,2016,32(23):2122-2124.
2021, Vol. 28 
